One of the most challenging dilemmas in oncology today involves the treatment of recurrent head and neck malignancies. Patients face daunting risks of disease recurrence and secondary cancers, with surgical options often limited due to tumor location or prior interventions. Addressing this precision gap, Dr. Taylor MacDonald and colleagues have meticulously reviewed 84 cases of proton re-irradiation at the Cancer Center. Their analysis reveals a sobering reality: more than 63% of patients experienced further disease progression within just four months post-treatment, while the one-year overall survival rate stood at 33%.

Proton re-irradiation represents a sophisticated modality whereby targeted proton beams deliver an additional course of radiation therapy to previously irradiated tissues, employing the physical properties of protons to minimize damage to surrounding healthy cells. MacDonald highlights that in absence of an established standard of care for recurrent cases, proton therapy provides an invaluable tool for enhancing local tumor control. Despite high-grade toxicities observed, these side effects were generally manageable, underscoring the critical need for judicious patient selection to balance therapeutic benefits against potential harms.

Looking ahead, the research team is focused on dissecting factors that exacerbate toxicity, particularly in patients with base-of-skull tumor recurrence—a subgroup for which long-term photon irradiation data remains scant. Their investigations are poised to inform safety enhancements and optimization of re-irradiation protocols that may transform outcomes in this recalcitrant patient population.

Complementing this work, Dr. Morgan Bailey and collaborators have conducted an insightful survey of expert radiation oncologists treating oropharyngeal cancers. Despite the prevalence of nearly 60,000 new oral cavity and oropharyngeal cancer cases annually in the United States, no standardized treatment paradigm has emerged. The survey exposed significant heterogeneity in therapeutic approaches among specialists across institutions, with implications reverberating from clinical trials to resident education and patient prognosis.

This stark variability reflects the complex interplay of tumor biology, technological capabilities, and clinician experience when navigating oropharyngeal cancer treatments. Bailey stresses how these findings urge a concerted effort to harmonize clinical guidelines and consolidate expertise in specialized academic centers to foster consistency that ultimately benefits patient outcomes.

Turning to hepatic malignancies, hepatocellular carcinoma (HCC) presents formidable therapeutic challenges due to its high intrahepatic recurrence rates and proximity to critical radiosensitive structures. Dr. Sarah Feldkamp’s study probes the safety profile of ablative radiation—a modality delivering concentrated high doses tailored to eradicate tumors—with an emphasis on hepatobiliary toxicity following treatment of centrally located HCC lesions. Remarkably, severe hepatobiliary complications were rare despite substantial radiation doses administered near sensitive biliary anatomy, indicating a favorable therapeutic index.

Such findings illuminate the increasing feasibility of precise ablative radiotherapy in managing difficult-to-treat liver tumors while preserving vital organ function. Feldkamp’s team intends to delve deeper into comparative toxicity across various ablative radiation regimens to further refine treatment planning and safeguard patient health.

Another pioneering evaluation from the same group examines the integration of patient-reported outcomes alongside clinician assessments in hypofractionated whole pelvis radiation for endometrial cancer. Hypofractionation shortens treatment duration by administering higher radiation doses per fraction, a strategy that has revolutionized breast and prostate cancer care. Their Phase 1 trial reveals a discrepancy: patients report higher rates of toxicity events compared to clinician evaluations, yet this does not correlate with diminished quality of life metrics.

This divergence underscores the intrinsic limitations of physician-only toxicity assessments and advocates for incorporating patient perspectives to capture the full spectrum of treatment impact. Feldkamp emphasizes that optimizing hypofractionated protocols could significantly improve convenience and adherence for endometrial cancer patients, pending validation of safety and efficacy.

Beyond these core studies, additional abstracts from the Cancer Center expand the frontier of radiation oncology knowledge. Jessica Ortega’s upcoming presentation investigates radiation necrosis, pseudoprogression, and radiologic changes after photon or proton chemoradiotherapy in IDH-mutated Grade 2-3 gliomas—tumors with distinct molecular and clinical profiles requiring nuanced therapeutic approaches.

Together, these comprehensive research efforts from the University of Cincinnati Cancer Center embody a relentless pursuit to enhance radiation oncology practice, guided by robust data and patient-centered inquiry. As technology advances and multidisciplinary collaboration deepens, these insights herald a new era of precision tailored not only to tumor biology but also to individual patient experience and safety.

Subject of Research: Radiation Oncology – Proton Re-irradiation in Head and Neck Cancers, Oropharyngeal Cancer Treatment Patterns, Hepatobiliary Toxicity in Liver Cancer, Hypofractionated Radiation in Endometrial Cancer

Article Title: University of Cincinnati Cancer Center Reveals Pioneering Radiation Oncology Findings at ASTRO 2025

News Publication Date: Not provided

Web References: Not provided

References: Not provided

Image Credits: Not provided

Keywords: Liver cancer, proton re-irradiation, head and neck cancer, oropharyngeal cancer, hepatocellular carcinoma, ablative radiation, hypofractionated radiation therapy, endometrial cancer, radiation toxicity, patient-reported outcomes

At the forefront of this research is Dr. Amar Kishan, UCLA’s executive vice chair of radiation oncology and co-director of the Cancer Molecular Imaging, Nanotechnology and Theranostics Program. Dr. Kishan will unveil pivotal results from the LUNAR clinical trial, which investigates the utility of 177Lutetium-PSMA, a radioligand therapy that specifically targets prostate-specific membrane antigen (PSMA) on prostate cancer cells. Administered preemptively before ablative radiotherapy, this therapy aims to eradicate oligorecurrent prostate cancer with enhanced specificity, potentially improving outcomes by delivering cytotoxic radiation directly to malignant cells while sparing healthy tissue. The trial’s findings are slated to be a highlight of ASTRO’s scientific discourse.

In parallel, the SCIMITAR phase II clinical trial’s four-year follow-up results will be presented by Dr. Jesus Juarez Casillas, co-chief resident at UCLA’s radiation oncology department. SCIMITAR evaluates stereotactic body radiation therapy (SBRT) administered post-prostatectomy to men at elevated risk for recurrence. The trial demonstrates sustained biochemical control, with 62% of participants remaining free from cancer recurrence after four years, a promising figure that rivals traditional fractionated radiotherapy regimens. These results are significant, exemplifying SBRT’s potential to deliver high-dose radiation with millimeter precision over fewer sessions, thereby improving patient convenience and reducing healthcare burden.

UCLA’s innovations further extend into the realm of imaging, where Dr. Daniel Low showcases pioneering work on 5DCT, an advanced imaging modality designed to capture lung tumor motion with exceptional fidelity in patients exhibiting irregular respiratory patterns. Unlike conventional four-dimensional CT (4DCT), which models tumor movement along spatial dimensions synchronized with breathing phases, 5DCT incorporates additional parameters—breath rate and depth—accounting for intra- and inter-breath variability. This enhanced modeling yields artifact-free, high-resolution tumor delineations, essential for precision radiotherapy planning that mitigates radiation exposure to surrounding healthy lung tissues.

MRI-guided radiotherapy also garners significant attention, with Dr. Travis Courtney presenting comparative analyses of MRI-guided stereotactic body radiotherapy (MRgSBRT) approaches for prostate cancer. His research contrasts standard high-dose MRgSBRT against an adaptive dose-painting strategy that delivers escalated radiation doses to dominant intraprostatic lesions while attenuating exposure to adjacent normal tissues. Preliminary results reveal elevated acute toxicities—namely urinary and gastrointestinal side effects—in the dose-painted cohort as assessed by clinicians, yet patient-reported quality of life remains comparable between methods. These findings underscore the delicate balance between intensifying tumoricidal action and preserving tissue integrity, warranting further investigation into optimizing dose distribution strategies.

Complementing this, Dr. Jonathan Massachi’s work on sexual function post-MRgSBRT in the MIRAGE trial sheds light on long-term physiological ramifications. Despite the superior soft tissue contrast afforded by MRI guidance facilitating nerve and vascular sparing, approximately one-third of men in both MRI- and CT-guided arms experienced marked declines in sexual function two years post-treatment. The data suggest that even sophisticated imaging cannot fully mitigate radiation-induced neurovascular damage, highlighting an urgent need for adjunct vessel-sparing techniques or systemic protective strategies in prostate cancer radiotherapy.

Beyond prostate cancer, Dr. Miriam Lane investigates postoperative SBRT for head and neck cancers, a domain traditionally managed by protracted radiotherapy courses. Her findings reveal that SBRT, when employed as a postoperative modality for newly diagnosed or recurrent tumors, offers a well-tolerated, condensed treatment course with minimal severe acute toxicities. However, roughly half of patients experienced local recurrence within two years, emphasizing the necessity for refined patient selection and combination therapies to improve durability of response. This research paves the way for integrating SBRT into multimodal head and neck cancer management paradigms.

On the molecular front, a study led by Dr. Beth Neilsen delves into the genetic landscape of radiation-resistant prostate cancers. Utilizing genomic and transcriptomic profiling, the investigation identified an enrichment of mutations in DNA repair genes such as BRCA1, BRCA2, RAD51B, and POLQ within locally recurrent tumors post-radiotherapy. These alterations correlate with aggressive disease features, elevated genomic risk scores, and diminished androgen receptor signaling, collectively elucidating mechanisms underpinning radioresistance. Such insights provide invaluable biomarkers for risk stratification and potential targets for radiosensitizing therapies, steering toward personalized radiation oncology.

Concurrently, the integration of digital innovation into cancer education is being championed by Dr. Trudy Wu, who will moderate a session dedicated to patient empowerment through technology. This panel will explore how narrated animations, interactive videos, and tailored digital resources can demystify complex oncologic information, reduce psychological distress, and enhance shared decision-making. By harnessing these tools, clinicians aspire to foster a more informed and engaged patient population, thereby improving adherence to treatment regimens and overall outcomes.

Collectively, these multifaceted advancements showcased by UCLA researchers epitomize a paradigm shift in radiation oncology, blending molecular science, imaging innovation, clinical trial rigor, and patient-centered education. This integrated approach not only augurs improved tumor control and reduced toxicities but also reinforces the holistic care imperative in contemporary oncology practice. The ASTRO 2025 meeting will undoubtedly serve as a crucible for disseminating these transformative findings, propelling the field toward new frontiers of precision and compassion.

Dr. Michael Steinberg, chair of radiation oncology at UCLA’s David Geffen School of Medicine and director of clinical affairs at the Jonsson Comprehensive Cancer Center, eloquently summarizes this momentum: “These UCLA-led studies embody the convergence of cutting-edge technology and collaborative expertise, charting a course toward safer, more precise, and more effective cancer therapies. Our commitment to innovation continues to energize efforts to overcome cancer’s myriad challenges and enhance patient lives.”

As these presentations unfold in late September, the oncology community and patients alike watch eagerly, anticipating the ripple effects these breakthroughs will inspire in radiation therapy protocols worldwide. UCLA’s leadership in this arena reaffirms its role as a beacon of cancer research excellence, transforming scientific discovery into tangible clinical benefit.

Subject of Research: Innovations in radiation therapy for prostate, lung, and head and neck cancers, including targeted radioactive treatments, advanced imaging techniques, and patient education.

Article Title: UCLA Researchers Unveil Cutting-Edge Radiation Oncology Breakthroughs at ASTRO 2025

News Publication Date: Late September 2025 (coinciding with ASTRO Annual Meeting)

Web References:

• UCLA Health Jonsson Comprehensive Cancer Center: https://www.uclahealth.org/cancer
• ASTRO Annual Meeting Abstracts Portal: https://amportal.astro.org/sessions/

Keywords: Radiation therapy, Prostate cancer, SBRT, 177Lutetium-PSMA, 5DCT imaging, MRI-guided radiotherapy, Radiosensitivity, Head and neck cancer, Cancer education, Precision oncology